
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Services-Offices & Clinics of Doctors of Medicine · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| Bevasiranib | Phase 2 | Macular Degeneration |
| Abaloparatide Transdermal (50 mcg) | Phase 2 | Post Menopausal Osteoporosis |
| Estradiol transdermal one 90 μL spray | Phase 3 | Hot Flashes |
| VeraCept | Phase 2 | Contraception |
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.